gefitinib has been researched along with 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (17-(dimethylaminoethylamino)-17-demethoxygeldanamycin) | Trials (17-(dimethylaminoethylamino)-17-demethoxygeldanamycin) | Recent Studies (post-2010) (17-(dimethylaminoethylamino)-17-demethoxygeldanamycin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 255 | 9 | 168 |
| Protein | Taxonomy | gefitinib (IC50) | 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (IC50) |
|---|---|---|---|
| Lysine-specific demethylase 6B | Homo sapiens (human) | 0.4 | |
| Lysine-specific demethylase 4B | Homo sapiens (human) | 0.7 | |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.1699 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.2724 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0036 | |
| Lysine-specific demethylase 5A | Homo sapiens (human) | 0.13 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.043 | |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | 0.0335 | |
| Lysine-specific demethylase 4C | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, M; Dote, H; Jida, M; Kawasaki, K; Kiura, K; Kobayashi, N; Kubo, T; Miyoshi, S; Ogino, A; Otani, H; Soh, J; Toyooka, S; Ueno, T; Yamamoto, H | 1 |
| Akashi, M; Chin, TM; Doan, NB; Koeffler, HP; Mori, S; Said, JW; Sudo, M | 1 |
2 other study(ies) available for gefitinib and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
| Article | Year |
|---|---|
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mutation; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |